Roughly two-thirds of schizophrenia patients fail to respond adequately to standard antipsychotics, and for that population the pharmacological toolkit has barely moved in decades. Against that backdrop, TG Therapeutics has opened a Phase 2 trial testing BRIUMVI (ublituximab-xiiy), its approved anti-CD20 therapy, in approximately 60 adults with treatment-resistant schizophrenia. The move is a genuine pivot: BRIUMVI carries an FDA indication for relapsing multiple sclerosis, and enrolling psychiatric patients represents a mechanistic bet that the disease shares enough immunological architecture with autoimmune neurological conditions to justify B-cell depletion as a therapeutic lever.
The biological rationale is credible but still developing. Research published in the American Journal of Psychiatry in 2015 was among the first to document elevated microglial activation in the brains of individuals at risk for and already diagnosed with schizophrenia, providing an early mechanistic anchor for immune-targeted approaches. More directly relevant to this trial, an open pilot study of 19 adults with treatment-resistant schizophrenia or OCD found that 6 of 9 schizophrenia patients (66.7%) met response criteria three to five months after a single infusion of rituximab 1000 mg added to existing therapy. That signal is preliminary and the cohort is small, but it anchors TG’s hypothesis in actual patient data rather than pure preclinical inference.
The trial design is open-label and single-arm, which means it is built to generate signal, not to confirm efficacy. Participants stay on background antipsychotic treatment throughout, and the primary endpoint is the proportion reaching at least a 20% reduction from baseline in PANSS total score at Week 12. That threshold is a conventional response definition in schizophrenia research, which makes the results interpretable against historical benchmarks. The infusion-reaction profile from BRIUMVI’s MS trials (48% incidence with premedication, 0.6% serious) is a real monitoring burden in a psychiatric setting, and the trial will need to demonstrate that operationalizing IV anti-CD20 therapy in this population is feasible before any larger randomized work becomes plausible. Clozapine remains the long-standing reference standard for treatment-resistant schizophrenia, carrying its own tolerability constraints, which frames the unmet need without overstating the competitive vacuum.
The number to track when results emerge is the PANSS responder rate against that 20% threshold. If it lands materially above what rituximab’s pilot data implied, TG has a credible basis to design a controlled Phase 3. If it matches or trails historical antipsychotic augmentation strategies, the immune-dysfunction hypothesis in schizophrenia absorbs another setback and the asset stays tethered to MS.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
